Cargando…

Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial

OBJECTIVE: To assess the efficacy of the Diabetes Medication Choice Decision Aid among patients with type 2 diabetes in Greece. DESIGN: Open-label cluster randomised controlled trial. SETTING: Primary and secondary care practices across Greece. PARTICIPANTS: 5 sites allocated to the decision aid (n=...

Descripción completa

Detalles Bibliográficos
Autores principales: Karagiannis, Thomas, Liakos, Aris, Branda, Megan E, Athanasiadou, Eleni, Mainou, Maria, Boura, Panagiota, Goulis, Dimitrios G, LeBlanc, Annie, Montori, Victor M, Tsapas, Apostolos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129072/
https://www.ncbi.nlm.nih.gov/pubmed/28186933
http://dx.doi.org/10.1136/bmjopen-2016-012185
_version_ 1782470527694143488
author Karagiannis, Thomas
Liakos, Aris
Branda, Megan E
Athanasiadou, Eleni
Mainou, Maria
Boura, Panagiota
Goulis, Dimitrios G
LeBlanc, Annie
Montori, Victor M
Tsapas, Apostolos
author_facet Karagiannis, Thomas
Liakos, Aris
Branda, Megan E
Athanasiadou, Eleni
Mainou, Maria
Boura, Panagiota
Goulis, Dimitrios G
LeBlanc, Annie
Montori, Victor M
Tsapas, Apostolos
author_sort Karagiannis, Thomas
collection PubMed
description OBJECTIVE: To assess the efficacy of the Diabetes Medication Choice Decision Aid among patients with type 2 diabetes in Greece. DESIGN: Open-label cluster randomised controlled trial. SETTING: Primary and secondary care practices across Greece. PARTICIPANTS: 5 sites allocated to the decision aid (n=101 patients) and 4 sites to control (n=103 patients). INTERVENTION: Clinicians and patients in the intervention arm used a decision aid, based on outcomes that both consider important when choosing among antihyperglycaemic medications. Patients in the control arm received usual care. OUTCOME MEASURES: The primary outcome was patient's level of decisional comfort after the initial clinical encounter. Secondary outcomes included patient's knowledge about type 2 diabetes and medications, and patient's and clinician's satisfaction. Adherence to prescribed antihyperglycaemic medication and change in glycated haemoglobin were assessed at 24 weeks. RESULTS: Patients in both arms had similar scores in overall decisional comfort (mean difference between the usual care and decision aid arms −6.9, 95% CI −21.5 to 7.7) and its subscales. Patients' knowledge was high in both arms (mean difference 2.3%, 95% CI −15.7% to 20.4%). Patients and clinicians in both groups were equally satisfied with the decision-making. No significant difference in medication adherence and glycaemic control was found across arms. Clinicians found the decision aid useful and reported that its integration in their daily routine was easy. CONCLUSIONS: The decision aid was implemented and positively received in the clinical setting in Greece, in line with the patient-centred approach endorsed by current guidelines. However, this trial yielded imprecise results in terms of patient outcomes. Further research is needed to investigate the interaction between the patient and the clinician in order to clarify the association between the use of decision aids and implementation of shared decision-making. TRIAL REGISTRATION NUMBER: NCT01861756. Pre-results.
format Online
Article
Text
id pubmed-5129072
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51290722016-12-02 Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial Karagiannis, Thomas Liakos, Aris Branda, Megan E Athanasiadou, Eleni Mainou, Maria Boura, Panagiota Goulis, Dimitrios G LeBlanc, Annie Montori, Victor M Tsapas, Apostolos BMJ Open Diabetes and Endocrinology OBJECTIVE: To assess the efficacy of the Diabetes Medication Choice Decision Aid among patients with type 2 diabetes in Greece. DESIGN: Open-label cluster randomised controlled trial. SETTING: Primary and secondary care practices across Greece. PARTICIPANTS: 5 sites allocated to the decision aid (n=101 patients) and 4 sites to control (n=103 patients). INTERVENTION: Clinicians and patients in the intervention arm used a decision aid, based on outcomes that both consider important when choosing among antihyperglycaemic medications. Patients in the control arm received usual care. OUTCOME MEASURES: The primary outcome was patient's level of decisional comfort after the initial clinical encounter. Secondary outcomes included patient's knowledge about type 2 diabetes and medications, and patient's and clinician's satisfaction. Adherence to prescribed antihyperglycaemic medication and change in glycated haemoglobin were assessed at 24 weeks. RESULTS: Patients in both arms had similar scores in overall decisional comfort (mean difference between the usual care and decision aid arms −6.9, 95% CI −21.5 to 7.7) and its subscales. Patients' knowledge was high in both arms (mean difference 2.3%, 95% CI −15.7% to 20.4%). Patients and clinicians in both groups were equally satisfied with the decision-making. No significant difference in medication adherence and glycaemic control was found across arms. Clinicians found the decision aid useful and reported that its integration in their daily routine was easy. CONCLUSIONS: The decision aid was implemented and positively received in the clinical setting in Greece, in line with the patient-centred approach endorsed by current guidelines. However, this trial yielded imprecise results in terms of patient outcomes. Further research is needed to investigate the interaction between the patient and the clinician in order to clarify the association between the use of decision aids and implementation of shared decision-making. TRIAL REGISTRATION NUMBER: NCT01861756. Pre-results. BMJ Publishing Group 2016-11-14 /pmc/articles/PMC5129072/ /pubmed/28186933 http://dx.doi.org/10.1136/bmjopen-2016-012185 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Diabetes and Endocrinology
Karagiannis, Thomas
Liakos, Aris
Branda, Megan E
Athanasiadou, Eleni
Mainou, Maria
Boura, Panagiota
Goulis, Dimitrios G
LeBlanc, Annie
Montori, Victor M
Tsapas, Apostolos
Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial
title Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial
title_full Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial
title_fullStr Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial
title_full_unstemmed Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial
title_short Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial
title_sort use of the diabetes medication choice decision aid in patients with type 2 diabetes in greece: a cluster randomised trial
topic Diabetes and Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129072/
https://www.ncbi.nlm.nih.gov/pubmed/28186933
http://dx.doi.org/10.1136/bmjopen-2016-012185
work_keys_str_mv AT karagiannisthomas useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial
AT liakosaris useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial
AT brandamegane useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial
AT athanasiadoueleni useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial
AT mainoumaria useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial
AT bourapanagiota useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial
AT goulisdimitriosg useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial
AT leblancannie useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial
AT montorivictorm useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial
AT tsapasapostolos useofthediabetesmedicationchoicedecisionaidinpatientswithtype2diabetesingreeceaclusterrandomisedtrial